Withdrawn plasma study leaves COVID-19 pneumonia treatment question unanswered
NCT ID NCT04333251
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test whether giving antibody-rich plasma from recovered COVID-19 patients could help hospitalized adults with pneumonia caused by the virus. The trial was withdrawn before any participants were enrolled, so no data was collected. The approach was based on the idea that donated antibodies might boost the immune response and reduce the need for oxygen or breathing support.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- convalescent plasma (antibody-rich blood plasma from recovered COVID-19 patients)
- What this could lead to
- If it had worked, this could have pointed toward a treatment for severe COVID-19 pneumonia using donated plasma from recovered patients.
- What could go wrong
- This trial was withdrawn before enrolling anyone, so no results are available. Convalescent plasma carries risks like allergic reactions or lung injury, and its effectiveness was uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 INTERSTITIAL PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.